US originators preparing an EU launch have, for decades, treated launch sequencing as a commercial decision calibrated against the same exclusivity architectures they navigate at home: Hatch-Waxman's five-year new-chemical-entity and three-year new-clinical-investigation exclusivities, the Medicare Part D negotiation cycle, and now the Inflation Reduction Act's selected-drug eligibility clock. The EU has run on a parallel logic. The relevant inputs at the EU launch table were familiar: which Member States offered first-cycle pricing premia, which would reference the others downward, which had public-procurement architectures that compressed margins, which were small enough to skip without strategic cost. Industry data, including IQVIA's annual W.A.I.T. Indicator survey published for the European Federation of Pharmaceutical Industries and Associations, indicate that newly authorised medicines reach their last EU Member State substantially later than their first, with the gap varying materially by therapeutic area and period. The EU Pharma Package compromise text published on 6 March 2026 does not abolish that asymmetry, but it changes its price. Article 56a of the new Directive gives any Member State a formal mechanism to demand launch, and Article 56a(5) terminates the EU regulatory market protection in that Member State if supply does not follow within three years. For a US-headquartered originator whose internal launch decisions have run on the Medicare-and-major-markets logic of the IRA, the question is no longer where to launch but what each skip now costs.
1. The Mechanism: How a Member State Launch Request Operates Under Article 56a
Article 56a of the Directive sits inside the chapter dealing with the obligations of the MAH and operates as a conditional overlay on the regulatory protection regime in Articles 80 and 81 of the same Directive. Its first paragraph is explicit on its scope: it applies to a medicinal product covered by a valid marketing authorisation in the territory of a Member State that is subject to regulatory protection under Article 80 or, if applicable, to orphan market exclusivity under Article 72 of the Regulation. Within that window, the Member State may request the holder to place the product on its market and to supply it so that the needs of patients in that Member State are covered as specified by the Member State.1Council compromise text for a Directive on the Union code relating to medicinal products for human use, ST-6367/26 (24 Feb 2026), Art. 56a. Paragraph 2 then specifies what the Member State may require the holder to do: submit a valid pricing and reimbursement application under national law, fulfil specific requirements in procurement procedures, or establish a roll-out plan agreed with that Member State, with the arrangements to implement those requirements being proportionate to the objective pursued and in compliance with Union law. Where the regulatory protection window has expired, the Member State retains the national pricing, procurement and supply tools it has always had; Article 56a itself, however, no longer engages.
The Member State must communicate its request within one year from the marketing authorisation, with explicit reference to Article 56a, and the holder and the Member State are then required to cooperate in good faith and to undertake best efforts, within the limits of their respective responsibilities, to ensure availability and supply. The roll-out plan itself is jointly drafted: the holder prepares it and the Member State agrees it, with either party able to require updates where developments such as evolving demand or changes in manufacturing or distribution capacity make the original plan obsolete. The drafting is deliberately bilateral, and the recital framing in the new Directive's recital (53b) makes clear that the Member State is not being given a unilateral pricing or volume-setting power. What it is given is the legal handle to put the holder under a defined, time-limited supply obligation with a regulatory consequence attached.
Article 56a converts the historical EU asymmetry of patient access into a conditional regulatory exclusivity: every Member State a US originator deliberately skips becomes a candidate for a request-driven loss of regulatory market protection in that territory three years after the request.
The mechanic that gives Article 56a its bite is its placement inside the regulatory-protection architecture rather than alongside it. Articles 80 and 81 of the Directive establish an eight-year regulatory data protection period followed by a market-protection period that runs for one year as a baseline and can be extended in several discretionary increments, including a further year where a new therapeutic indication is authorised during the data-protection period that brings significant clinical benefit, plus six-month extensions for unmet medical need and for comparator clinical trials, with a cumulative cap.2ST-6367/26 (n 1), Art. 80(1)–(2) and Art. 81(2)–(2b) (8+1 baseline plus discretionary extensions). Article 56a(5) does not touch the data-protection layer; it disapplies, in the requesting Member State only, the market-protection layer in Article 80(2) and any prolongation of that period under Article 81. The intervention is surgical, but the value at stake is not: in indications where generic or biosimilar entry materially shifts revenue, one year of stripped market protection in a Member State is the difference between an extra year of branded sales and an extra year of erosion.
For centrally authorised products, the configuration that dominates the US-originator portfolio, Article 5a of the Regulation establishes a parallel obligation to supply at Union level. Its scope is, in one important respect, wider than Article 56a's: it reaches products subject not only to regulatory protection under Article 80 of the Directive or orphan exclusivity under Article 72 of the Regulation, but also to patent or supplementary protection certificate, typically a materially longer window for a US-originator blockbuster. Within that wider scope a Member State may either pursue the Article 56a route through the Directive or proceed independently under Article 5a; the same narrowly drawn force-majeure carve-out applies in identical wording, with recital (11a) of the Regulation adding a further Article-5a-specific saving consideration providing that the obligation should not compromise the financial viability of the company.
The procedural consequence, however, differs structurally from Article 56a(5). Article 5a(2) opens a Commission-escalation route gated by a four-week holder-observation window; paragraph 3 requires the Commission, where more than one Member State invokes paragraph 2 against the same product, to bring the holder into good-faith negotiations; paragraph 4 requires the Commission to report four years after the date of application on whether legislative proposals are needed to introduce penalties under Article 172 of the Regulation. Those penalties (Commission-imposed fines up to 5% of the holder's Union turnover in the preceding business year, plus periodic penalty payments up to 2.5% of average daily Union turnover) apply only to the obligations enumerated in Annex II of the Regulation, and Article 5a is not currently listed there. Until the Commission's four-year report becomes a legislative vehicle that adds Article 5a to Annex II, the immediate teeth of Article 5a are the Commission-dialogue track, not a financial-penalty track. The contrast with Article 56a(5) is therefore structural rather than incremental: Article 56a delivers a self-executing regulatory consequence at the three-year mark; Article 5a delivers a Commission-supervised compliance dialogue whose financial-penalty teeth depend on future legislative action.3ST-6367/26 (n 1), Art. 56a(5)–(6); Reg ST-6366/26, Art. 5a, Art. 72(2), Art. 172 + Annex II, recital (11a).
The transitional architecture is correspondingly narrow. Article 219(1a) of the Directive allows Member States to begin applying Article 56a from twelve months after entry into force, but only in respect of products authorised after entry into force; products already on the EU market on the relevant date are insulated. A second subparagraph addresses the interim window between entry into force and date of application: for products authorised under Regulation 726/2004 or Directive 2001/83 during that period, a requesting Member State that has not received supply may disapply the second subparagraph of Article 10(1) of the old Directive (the ten-year market-protection rule under the legacy 8+2(+1) regime), accelerating generic or biosimilar entry into the requesting Member State by up to two years, or up to three where the +1 significant-clinical-benefit extension would otherwise have applied.
2. The Three-Year Clock and Loss of Market Protection in That Territory
Article 56a(5) sets out the consequence in operational terms. Where, within three years after a Member State submitted its request under paragraph 2, the holder has not, within the limits of its responsibilities, made the medicinal product available and has not supplied it continuously within that period so that the needs of patients in the requesting Member State are covered, the market protection under Article 80(2) and any prolongation of market exclusivity for orphans under Article 72(2) of the Regulation do not apply within that Member State, and Article 166(5) of the Directive applies. The three-year clock therefore runs not from authorisation, not from refusal of a pricing application, and not from any failure of negotiation in isolation, but from the date of the Member State's formal request under paragraph 2. The starting gun is procedural; the consequence at the finish is substantive.
Two features of the three-year construction deserve attention. The first is that the consequence is geographically partitioned. Loss of market protection applies only in the requesting Member State; the holder's protection elsewhere in the Union is undisturbed. The second is that the consequence is asymmetric in time. The data-protection layer in Article 80(1) continues to bar a generic or biosimilar applicant from relying on the originator's pre-clinical and clinical data for the standard period. What lapses is the further market-protection year (and any extensions of it under Article 81). Article 56a(6) goes further by accelerating the procedural runway for that generic or biosimilar entrant: where a Member State has made the information about a lapse publicly available under paragraph 5a, a generic or biosimilar application referring to that reference product may be validated and assessed by the national competent authority or the European Medicines Agency from six years after the start of the data-protection period of the reference medicinal product, even though the marketing authorisation itself may not be granted prior to the expiry of the regulatory data-protection period. The operational consequence is that the generic applicant can begin the regulatory assessment process up to two years before the originator's data-protection period expires, with an authorisation issuing on day one of the now-stripped market-protection window; the doctrinal acceleration of generic entry is amplified, not just by the lost year of market protection, but by the procedural readiness of the generic applicant to capitalise on it. That procedural acceleration is reinforced by the parallel widening of the Bolar exemption elsewhere in the new framework, which allows the generic applicant to prepare pricing, reimbursement, and tender-submission steps without infringement risk during the same window.See further the firm's analysis of the new Bolar architecture under the EU Pharma Package.
For an originator whose European pricing model assumed eight-plus-one or eight-plus-one-plus-one years of exclusivity in every Member State, the value at stake is not abstract. The Pharma Package's compromise design preserved a one-year baseline market protection precisely because that final year is, in many indications, the carrier of the originator's last unimpeded margin year before biosimilar or generic erosion. Stripping it in a single Member State opens a recognised first-mover window for a generic competitor in that territory and accelerates the cross-border price-reference signal to higher-price markets that have launched on time. That window presupposes a particular configuration, however. Because Article 56a(5) reaches only the regulatory market-protection layer, the lapse accelerates generic or biosimilar entry only where patent and supplementary protection certificate cover have already fallen away in the Member State concerned: for a product still shielded by a patent or supplementary protection certificate when the market-protection year would otherwise run, the stripped year changes nothing the originator can monetise, and the sanction bites hardest on products for which regulatory market protection is the last barrier to entry. On the orphan side the consequence runs through Article 72(2): Article 56a(5) reaches the prolongation of orphan market exclusivity, so a US rare-disease originator can lose those additional twelve-month increments, grantable up to twice for new orphan indications and stacked on top of the nine- or eleven-year base exclusivity, in a Member State whose request it did not, or could not, satisfy. The originator's revenue exposure is the product of the indication's value in the affected Member State, the length of any Article 81 extension or orphan prolongation that would otherwise have applied, and the speed at which a generic or biosimilar entrant capitalises on the open door.
3. Defences, Force Majeure, and Reimbursement-Deadlock Treatment
The defences available to a holder facing the three-year clock are textually narrow. Article 56a(8) contains the operative carve-out: holders shall comply with the obligations set out in this Article, except for exceptional and unforeseeable circumstances, including those related to disruptions of supply, or duly justified circumstances fully outside the holder's control, the consequences of which could not have been avoided even if all best and reasonable measures had been taken; the holder must provide an explanation of the case and circumstances and justify the reasons for non-compliance. The drafting traces the architecture of EU force-majeure case-law without reproducing it verbatim, and three structural features stand out. The carve-out is built from two alternative limbs: the first reaching exceptional and unforeseeable circumstances (expressly including supply disruptions), the second duly justified circumstances fully outside the holder's control and unavoidable despite all best and reasonable measures. Each limb is internally cumulative, but a holder need satisfy only one, and both set a demanding threshold. The carve-out's reference to disruptions of supply tracks the shortages framework of Chapter X of the Regulation rather than introducing an independent supply-failure defence. And the burden of proof, by the textual logic of the saving clause, sits on the holder.
The defences the text does not mention are at least as important as the one it does. The recital framing in recital (53a) of the Directive describes the policy rationale, namely that practice shows the placing on the market of authorised medicinal products does not occur, is delayed, or occurs in quantities that do not correspond to the needs of those Member States; but the recital does not translate that framing into a textual defence of good-faith pricing-and-reimbursement deadlock. A holder that has submitted a valid pricing application under Article 56a(2)(a) within the agreed roll-out plan, that has engaged the national pricing authority in good faith, and that has nonetheless failed to reach agreement within the three-year window is not on its face protected by paragraph 8: a pricing disagreement is on its face neither an exceptional and unforeseeable circumstance nor one fully outside the holder's control. Given the absence of any textual reference to pricing or reimbursement disagreements in Article 56a(8) and the narrowly drawn, EU-force-majeure-inspired wording of both limbs, it is at best uncertain whether a reimbursement deadlock that is not attributable to the holder, particularly where the Member State has shifted its pricing benchmark mid-procedure or has refused to commence the procedure at all, would qualify; this is the area in which early national case-law and possible preliminary references to the Court of Justice will be pivotal.
The procedural-review landscape compounds the substantive uncertainty. The loss of market protection is the automatic legal consequence of the factual situation described in Article 56a(5); there is no separate Union-level declaration of non-compliance before the lapse takes effect, no Article 56a hearing, no independent finding of non-compliance prior to the loss of market protection. The Member State's function under paragraph 5a is to notify and publicise that consequence and, for centrally authorised products, to notify the European Medicines Agency; it is recognition of the lapse, not creation of it. The Pharmaceutical Committee under paragraph 8 may exchange views on national measures envisaged in the event of non-compliance, but its function is consultative rather than adjudicative. The judicial route, where a holder seeks to contest a Member State's invocation of paragraph 5, runs through national administrative-law proceedings in the requesting Member State, with the prospect of Article 267 TFEU referral to the Court of Justice on the interpretation of paragraph 8's saving clause. The temporal asymmetry that follows is structural: the lapse takes effect operationally before any court has ruled on whether the conditions for invoking it were satisfied. A holder that prevails in litigation three or four years later may recover damages, but the generic or biosimilar entrant whose Article 56a(6) application was validated in the meantime has, by then, already entered the territory.
4. Coordination Risk: Can Member States Effectively Coordinate Requests?
The text of Article 56a is, with deliberate precision, a Member-State-by-Member-State mechanism. Each Member State acts in its own name, on its own timetable, with its own roll-out plan. There is no provision for a coordinated Union-level request, no joint-procedure path through any of the existing inter-Member-State regulatory coordination bodies, and no role for the Commission in initiating or sequencing requests. Paragraph 8 contemplates only that Member State representatives may request the Commission to discuss issues related to the practical application of the Article in the Pharmaceutical Committee established by Council Decision 75/320/EEC,4Council Decision 75/320/EEC of 20 May 1975 setting up a pharmaceutical committee [1975] OJ L147/23, as referenced in ST-6367/26 (n 1), Art. 56a(8). with bodies responsible for health technology assessment under Regulation (EU) 2021/2282 and national pricing-and-reimbursement bodies invitable to deliberations as required. The Pharmaceutical Committee's mandate, the Decision makes clear, is consultative; it does not transform into a coordinating organ by virtue of paragraph 8.
The structural consequence is that coordination, if it happens at all, will happen through the informal pricing-and-reimbursement networks that already exist outside the Pharma Package. Beneluxa, the cooperation among Belgium, the Netherlands, Luxembourg, Austria and Ireland on horizon scanning, health technology assessment and joint price negotiation, is the most institutionally developed of these; the Valletta Declaration network of southern European Member States and the Nordic Pharmaceutical Forum operate on parallel logics with different memberships. None of these networks has Article 56a authority; none can issue a coordinated launch request that legally binds participating Member States to act in concert. What they can do, and what their pricing-cooperation work already shows they do, is exchange information on negotiating positions, on launch-timing patterns, and on holder behaviour across markets. A coordinated wave of Article 56a requests from Beneluxa members targeting the same product would not be a coordinated request in the legal sense, but it would be operationally indistinguishable from one for the holder on the receiving end.
The first-mover incentive that follows is asymmetric and, for the small or low-price Member State, attractive. A Member State acting alone bears the entire administrative cost of preparing the request, agreeing the roll-out plan, and monitoring compliance, but captures only its own share of the consequence: market protection lapses in its territory only, the generic or biosimilar window opens only there, and the price-reference signal to other Member States is a side effect rather than the primary objective. For a small Member State whose health system would otherwise wait years for the originator's voluntary launch, the calculus is plain: the cost of acting first is fixed, the benefit is captured immediately, and the risk of being undercut by a faster-moving peer is low precisely because peers face the same fixed cost. For a large Member State whose internal market the originator launches into on commercial logic anyway, the calculus is the reverse: the marginal benefit of an Article 56a request is small, because the launch is already happening, and the administrative cost remains. The mechanism's incentive structure pushes adoption into precisely the Member States the originator's launch strategy has historically deprioritised.
5. The Interaction with Parallel Trade and EU-Wide Pricing Negotiation Leverage
Article 56a's drafters did anticipate that an originator under three-year pressure might launch into a low-price Member State at concessionary pricing precisely to stop the clock. Whether the strategy survives parallel trade is a separate question. The EU exhaustion doctrine in the medicines context, settled across the Court of Justice's Centrafarm, Bristol-Myers Squibb and Boehringer jurisprudence, treats a product placed on the market in one Member State with the holder's consent as exhausted for free-movement purposes; parallel exports from the lower-price Member State to higher-price Member States cannot be blocked on intellectual-property grounds alone.5Centrafarm (Case 15/74), Bristol-Myers Squibb v Paranova (Joined Cases C-427/93, C-428/93 and C-429/93) and Boehringer Ingelheim v Swingward (Case C-143/00): EU exhaustion and the repackaging of parallel-imported medicines. The Pharma Package does not disturb that baseline. What it adds, through Article 166(5) of the new Directive, is an asymmetric carve-out: where market protection has lapsed in a Member State under Article 56a(5), wholesale distributors and distance-selling operators are barred from making the generic, biosimilar, hybrid or biohybrid medicinal product available on the market of another Member State where the protection still applies, during the period of that protection.6ST-6367/26 (n 1), Art. 56a(5a) and Art. 166(5) (asymmetric wholesale-distribution carve-out: bars generic export from lapsed-protection MS into protection-intact MS). Wholesalers must keep specific records for three years where the product is intended for export to another Member State in which protection periods do not apply pursuant to Article 56a(5).
The carve-out is one-directional and constrains only the generic side. The originator's own product, launched in the low-price Member State to defeat the request, remains subject to ordinary free-movement rules; parallel exporters can buy it at the lower price and resell it into a higher-price Member State without an Article 166(5) barrier. The economic effect runs in the direction the architecture predicts. An originator that capitulates to a Member State request by launching at a concessionary price has not insulated its pricing in the rest of the Union; it has, on the contrary, opened a parallel-trade arbitrage channel that erodes price discipline in the higher-price Member States that launched on time, with the additional irony that those higher-price Member States are precisely the ones whose negotiating leverage was already greater than the requesting Member State's. Existing analysis of parallel-import dynamics under Swiss and EU exhaustion law captures the directional logic and its operational consequences in more detail than the Pharma Package's framing requires.See further the firm's analysis of parallel-import exposure in pharma distribution agreements.
The EU-wide pricing-negotiation consequence is the second-order effect that matters more than the first-order revenue arithmetic. An originator's leverage in pricing negotiations with high-price Member States has historically rested on the credibility of the threat to skip lower-price Member States that would otherwise reference downward, and on the credibility of a withdrawal threat where the offered price was unattractive. Article 56a degrades the first leg of that leverage by attaching a cost to the skip; it degrades the second leg by attaching a cost to the withdrawal-equivalent outcome of failing to supply for three years post-request. The remaining originator response, launching everywhere at a defensible price, moves toward the availability-in-all-Member-States objective that the policy framing in recital (45) and recital (53a) sets out, even as those recitals leave pricing and reimbursement to Member-State competence. Whether US originators whose internal pricing committees were calibrated on Medicare Part D and the IRA's negotiation framework can absorb that EU-wide price-discipline shift without re-pricing their global launch model is, for now, unresolved.
6. Strategic Considerations: Selective Launch, Pricing Sequencing, and the Swiss Reference
Several unresolved questions follow from Article 56a. The first is whether a US originator still has a credible skip-this-country threat that Member States believe. The pre-Pharma-Package version of the threat rested on the simple proposition that the originator could decline to file a pricing application, or could withdraw if the price offered was unattractive, with no further consequence than lost revenue in that market. The new architecture does not eliminate the threat; it converts it into a conditional one. A Member State that has not exercised its Article 56a authority leaves the historical posture intact, and small Member States with limited administrative capacity may, for reasons unrelated to the originator's product, decline to invoke the mechanism at all. But the credibility of the threat now turns on a Member-State-specific judgement about which Member States are likely to act, on what timetable, and how a request that the originator concedes to mid-three-year-window will be valued against a request the originator contests to the end. The threat is no longer an across-the-board commercial posture; it is a portfolio of bilateral judgements, each of which the originator's regulatory affairs and commercial functions are unaccustomed to making together.
A related and structurally harder question is whether early launch at a low reference price in one Member State, undertaken to defeat an Article 56a request, damages EU-wide pricing more than the regulatory exclusivity it preserves. The arithmetic turns on variables the Pharma Package does not fix: parallel-trade exposure, reference-pricing cascades, indication-specific generic or biosimilar entry speed, and the breadth of the parallel-trade-permissive distributor network in the affected Member State. The non-orthodox component is that the answer depends on facts the originator's pricing committee has not historically priced together. The reference-pricing exposure of a Member State that has hitherto been excluded from the originator's reference-pricing model because no launch occurred there is unmeasured. The parallel-export potential of a distributor footprint built up to serve, rather than evade, the originator's launch decisions is unquantified. And the substitution effect of a generic or biosimilar entrant whose Article 56a(6) window opens six years after data-protection commencement, rather than at the standard regulatory-protection horizon, has no historical comparator to calibrate against.
Then there is the Swiss-reference question, which, for a Swiss-anchored practice, is unavoidable. Switzerland is a third country to the EU for medicinal-product authorisation, with Swissmedic authorising independently of the EU procedures, and Article 56a's textual scope is Member State only; the mechanism does not give Swissmedic a parallel authority over a holder's Swiss launch decisions, and the Swiss authorisation framework under the HMG remains structurally distinct from the centralised and decentralised procedures the Pharma Package amends. Whether Swiss pricing becomes a sequencing tool in the EU context is therefore a question of cross-border reference-pricing architecture rather than of EU regulatory law. The directional logic favours Swiss-first sequencing where the originator seeks a high-price reference anchor that does not generate Article 56a exposure, but that very sequencing already drew regulatory and political scrutiny in the Swiss three-year reference-price review work the firm has covered in companion analysis.See further the firm's analysis of Swiss pharma pricing under the three-year reference-price review. Whether a Swiss-first sequence remains tactically attractive once EU Member States internalise it as a signal of the originator's pricing position is the question the architecture leaves unresolved.
The US-originator-specific overlay turns on the Inflation Reduction Act's price-negotiation timing and the US launch-first norm. The IRA's Medicare drug-price-negotiation framework operates on time-since-FDA-approval thresholds (a small-molecule drug becomes negotiation-eligible seven years after FDA approval and a biologic eleven years after licensure, with the negotiated price taking effect two years later in each case), and US originators are increasingly designing launch-and-pricing strategies with that clock in mind, even where the empirical record of how originator behaviour has actually shifted in response remains thin.7Inflation Reduction Act of 2022, Pub L No 117-169, §§ 11001–11003 (codified principally at 42 USC §§ 1320f to 1320f-7). The intersection with Article 56a is unstable in two respects. The US launch-first norm means that the EU launch falls into the window that Article 56a measures from the European authorisation date, with the result that an EU pricing-negotiation cycle compressed by Article 56a may collide with a US pricing decision that the originator is simultaneously making under IRA-eligibility logic. The directional consequence is that a price set in a low-price Member State to defeat an Article 56a request, then propagated through the EU's reference-pricing cascade into Germany, the Netherlands, the Nordic countries and beyond, becomes a data point that the IRA negotiation will see when the US negotiation window opens. Whether the originator's US pricing posture can absorb a globally lower EU reference price as the cost of avoiding Article 56a exposure, or whether the IRA collision forces the originator into a re-engineered launch sequence that absorbs the Article 56a cost in exchange for protecting the US pricing anchor, is a question that no single function inside a US originator is institutionally positioned to answer.
The deepest question Article 56a raises, on the analysis offered here, is whether the mechanism inadvertently re-prices the centralised marketing authorisation itself. The pre-Pharma-Package centralised authorisation conferred a right to place the product on the Union market that the originator could exercise or not exercise at its discretion; the regulatory protection period that attached to it ran by operation of law from the authorisation date and did not depend on the originator's launch decisions in any particular Member State. Article 56a converts that absolute right into a contingent one: in every Member State that exercises its paragraph 1 authority, the regulatory protection becomes contingent on a supply outcome the originator can be required to deliver on a roll-out plan it has agreed under regulatory pressure. The contingency is bounded, operating only Member State by Member State and only on the market-protection rather than the data-protection layer, but the architectural shift is real. Whether the centralised authorisation, going forward, is best understood as a Union-wide commercial right with conditional exclusivity carve-outs in particular Member States, or as a bundle of Member-State-specific conditional rights tied together by a single regulatory dossier, is itself a characterisation question. The answer matters: it affects how the right is valued in M&A diligence, how it is treated in licensing agreements, and how it is described to investors. The Directive itself recognises that the mechanism is experimental: Article 216(1) of the Directive requires the Commission, approximately a decade after the new framework's date of application, to report to the European Parliament and the Council on the application of the access-facilitating provisions in Article 56a, including whether they have in practice delivered timely availability and continuous supply in the Member States that have applied them, with the possibility of further legislative change in light of that experience. These are questions that require analysis tailored to the specific product, indication, and Member-State configuration, and to commercial facts that are rarely shareable in a single document.